Nail outcome improvements with certolizumab pegol in moderate to severe plaque psoriasis: results from phase 3 trials

被引：0
|
作者：
Gottlieb, A. B. [1 ]
Thaci, D. [2 ]
Leonardi, C. [3 ,4 ]
Poulin, Y. [5 ]
Kavanagh, S. [6 ]
Boehnlein, M. [7 ]
Reich, K. [8 ,9 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Univ Lubeck, Lubeck, Germany
[3] Cent Dermatol, St Louis, MO USA
[4] St Louis Univ, Sch Med, St Louis, MO USA
[5] Ctr Rech Dermatol Quebec Metropolitain, Quebec City, PQ, Canada
[6] UCB Pharma, Raleigh, NC USA
[7] UCB Pharma, Monheim, Germany
[8] SCIderm Res Inst, Hamburg, Germany
[9] Dermatologikum Berlin, Berlin, Germany
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2019年 / 33卷
关键词：
Certolizumab Pegol; Nail disease; Psoriasis;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P116
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [21] Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy
    Imafuku, Shinichi
    Tada, Yayoi
    Umezawa, Yoshinori
    Sakurai, Shinya
    Hoshii, Naoki
    Nakagawa, Hidemi
    DERMATOLOGY AND THERAPY, 2022, 12 (01) : 121 - 135
  • [22] Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy
    Shinichi Imafuku
    Yayoi Tada
    Yoshinori Umezawa
    Shinya Sakurai
    Naoki Hoshii
    Hidemi Nakagawa
    Dermatology and Therapy, 2022, 12 : 121 - 135
  • [23] Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials
    Blauvelt, A.
    Reich, K.
    Lebwohl, M.
    Burge, D.
    Arendt, C.
    Peterson, L.
    Drew, J.
    Rolleri, R.
    Gottlieb, A. B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (03) : 546 - 552
  • [24] Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial
    Eyerich, Kilian
    Gottlieb, Alice B.
    Piaserico, Stefano
    Beissert, Stefan
    Gooderham, Melinda
    Kirby, Brian
    Tilt, Nicola
    Madden, Cynthia
    Wiegratz, Susanne
    de Cuyper, Dirk
    Elewski, Boni
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB22 - AB22
  • [25] Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
    Eyerich, Kilian
    Gottlieb, Alice B.
    Piaserico, Stefano
    Beissert, Stefan
    Gooderham, Melinda
    Kirby, Brian
    Tilt, Nicola
    Madden, Cynthia
    Wiegratz, Susanne
    de Cuyper, Dirk
    Merola, Joseph F.
    Elewski, Boni
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4467 - 4469
  • [26] Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3
    Dennehy, Ellen B.
    Zhang, Lu
    Amato, David
    Goldblum, Orin
    Rich, Phoebe
    JOURNAL OF DRUGS IN DERMATOLOGY, 2016, 15 (08) : 958 - 961
  • [27] Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
    Gordon, Kenneth B.
    Langley, Richard G.
    Warren, Richard B.
    Okubo, Yukari
    Gold, Linda Stein
    Merola, Joseph F.
    Peterson, Luke
    Wixted, Krista
    Cross, Nancy
    Deherder, Delphine
    Thaci, Diamant
    JAMA DERMATOLOGY, 2022, 158 (07) : 735 - 744
  • [28] Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial
    Warren, R. B.
    Lebwohl, M.
    Sofen, H.
    Piguet, V.
    Augustin, M.
    Brock, F.
    Arendt, C.
    Fierens, F.
    Blauvelt, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (12) : 2398 - 2408
  • [29] Bimekizumab in patients with moderate-to-severe plaque psoriasis by bodyweight: pooled results from phase III trials
    Pinter, A.
    Strober, B.
    Rosmarin, D.
    Gisondi, P.
    Vanvoorden, V.
    Peterson, L.
    Madden, C.
    de Cuyper, D.
    Warren, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E48 - E49
  • [30] Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension
    Reich, K.
    Ortonne, J. -P.
    Gottlieb, A. B.
    Terpstra, I. J.
    Coteur, G.
    Tasset, C.
    Mease, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (01) : 180 - 190
12345